SynthesisDiabetologia2022

SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.

Elisa Marilly et al.PubMed ↗Publisher ↗

No numbers read from the abstract.